This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008 Apr 15;46(8):1152-6.

doi: 10.1086/533442.

Reassessing the design, conduct, and analysis of clinical trials of therapy for community-acquired pneumonia

PMID: 18444849
DOI: 10.1086/533442

Editorial

Reassessing the design, conduct, and analysis of clinical trials of therapy for community-acquired pneumonia

John H Powers. Clin Infect Dis. 2008.

. 2008 Apr 15;46(8):1152-6.

doi: 10.1086/533442.

Author

PMID: 18444849
DOI: 10.1086/533442

No abstract available

PubMed Disclaimer

Comment on

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Pertel PE, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M, Thorne GM, Luperchio SA, Arbeit RD, Alder J. Pertel PE, et al. Clin Infect Dis. 2008 Apr 15;46(8):1142-51. doi: 10.1086/533441. Clin Infect Dis. 2008. PMID: 18444848 Clinical Trial.

Similar articles

Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
Gilbert DN. Gilbert DN. Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S121-2. doi: 10.1086/591391. Clin Infect Dis. 2008. PMID: 18986276
Comments on: Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin and comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Cifaldi MA. Cifaldi MA. Curr Med Res Opin. 2004 Dec;20(12):1895-6; author reply 1896-7. doi: 10.1185/030079904X11600. Curr Med Res Opin. 2004. PMID: 15701207 No abstract available.
Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
Tillotson GS, Echols RM. Tillotson GS, et al. Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S237-40. doi: 10.1086/591408. Clin Infect Dis. 2008. PMID: 18986296 Review.
Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM, Tillotson GS, Song JX, Tosiello RL. Echols RM, et al. Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S166-75. doi: 10.1086/591399. Clin Infect Dis. 2008. PMID: 18986284 Review.
Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.
Bradley JS, McCracken GH. Bradley JS, et al. Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S241-8. doi: 10.1086/591410. Clin Infect Dis. 2008. PMID: 18986297 Review.

See all similar articles

Cited by

Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.
Powers JH. Powers JH. Clin Infect Dis. 2010 Aug 1;51 Suppl 1(Suppl 1):S18-28. doi: 10.1086/653036. Clin Infect Dis. 2010. PMID: 20597667 Free PMC article. Review.
Looking for new strategies to combat an old foe.
Metlay JP. Metlay JP. J Hosp Med. 2013 Feb;8(2):59-60. doi: 10.1002/jhm.2005. Epub 2013 Jan 18. J Hosp Med. 2013. PMID: 23335255 Free PMC article. No abstract available.
Issues in noninferiority trials: the evidence in community-acquired pneumonia.
Fleming TR, Powers JH. Fleming TR, et al. Clin Infect Dis. 2008 Dec 1;47 Suppl 3(Suppl 3):S108-20. doi: 10.1086/591390. Clin Infect Dis. 2008. PMID: 18986275 Free PMC article. Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

N01-CO-12400/CO/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information